Impact of IgG subclass on molecular properties of monoclonal antibodies

MAbs. 2021 Jan-Dec;13(1):1993768. doi: 10.1080/19420862.2021.1993768.

Abstract

Immunoglobulin G-based monoclonal antibodies (mAbs) have become a dominant class of biotherapeutics in recent decades. Approved antibodies are mainly of the subclasses IgG1, IgG2, and IgG4, as well as their derivatives. Over the decades, the selection of IgG subclass has frequently been based on the needs of Fc gamma receptor engagement and effector functions for the desired mechanism of action, while the effect on drug product developability has been less thoroughly characterized. One of the major reasons is the lack of systematic understanding of the impact of IgG subclass on the molecular properties. Several efforts have been made recently to compare molecular property differences among these IgG subclasses, but the conclusions from these studies are sometimes obscured by the interference from variable regions. To further establish mechanistic understandings, we conducted a systematic study by grafting three independent variable regions onto human IgG1, an IgG1 variant, IgG2, and an IgG4 variant constant domains and evaluating the impact of subclass and variable regions on their molecular properties. Structural and computational analysis revealed specific molecular features that potentially account for the differential behavior of the IgG subclasses observed experimentally. Our data indicate that IgG subclass plays a significant role on molecular properties, either through direct effects or via the interplay with the variable region, the IgG1 mAbs tend to have higher solubility than either IgG2 or IgG4 mAbs in a common pH 6 buffer matrix, and solution behavior relies heavily on the charge status of the antibody at the desirable pH.

Keywords: IgG subclass; Monoclonal antibodies; homology modeling; hydrophobicity; isoelectric point; solubility; thermal unfolding; turbidity; viscosity.

MeSH terms

  • Antibodies, Monoclonal* / chemistry
  • Antineoplastic Agents, Immunological*
  • Humans
  • Immunoglobulin G
  • Receptors, IgG

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • Immunoglobulin G
  • Receptors, IgG

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.